TY - JOUR
T1 - Upregulation of FOXP3+Regulatory T Lymphocytes and CD8+Lymphocytes in Patients with High-Grade Squamous Intraepithelial Lesions Correlated with HPV Infection
AU - Mitiļdžans, Androniks
AU - Zablocka, Tatjana
AU - Isajevs, Sergejs
AU - Gordjušina, Valentina
AU - Rezeberga, Dace
N1 - Raksts ir publicēts 2022.gada aprīlī. Tas redzams žurnāla publikācijā, raksta PDF publikācijā un Web of Science publikācijā.
Scopus datubāzē publicēšanas gads ir norādīts kļūdaini kā 2021.gads.
Publisher Copyright:
© Latvian Academy of Sciences.
PY - 2022/4
Y1 - 2022/4
N2 - Modern therapeutic strategies for precancerous cervical intraepithelial neoplasia (CIN) focus on immune-modulatory and cancer vaccination. The local cervical immune status in cervical cancer and CIN could influence HPV infection persistence, progression and carcinogenesis. We analysed the role of FOXP3+ regulatory T lymphocytes, CD4+ and CD8+ T lymphocytes in CIN I, CIN II and CIN III patients with and without HPV infection. Sixty-two patients were enrolled in the study. Each patient underwent a colposcopy-guided cervical biopsy. FOXP3+ lymphocytes and CD4+,CD8+ lymphocytes were detected by immunostaining in tissue samples obtained from a control group (n = 10), patients with CIN I (n = 20), CIN II (n = 14) and CIN III (n = 18) lesions. HPV was assayed by Aptima. The results showed that the numbers of CD4+ T lymphocytes did not differ between patients with CIN I, CIN II, and CIN III. However, patients with CIN II and CIN III had significantly upregulated CD8+T lymphocytes compared to patients with CIN I. In addition, patients with CIN II and CIN III had increased FOXP3 + T lymphocytes compared with patients with CIN I, which was associated with HPV status. Upregulation of FOXP3+ regulatory T lymphocytes and CD8-positive lymphocytes in patients with CIN II and CIN III suggested a pivotal role of T regulatory lymphocytes and CD8+ lymphocytes for counteracting the host immune response in the progression from CIN I to CIN II and CIN III.
AB - Modern therapeutic strategies for precancerous cervical intraepithelial neoplasia (CIN) focus on immune-modulatory and cancer vaccination. The local cervical immune status in cervical cancer and CIN could influence HPV infection persistence, progression and carcinogenesis. We analysed the role of FOXP3+ regulatory T lymphocytes, CD4+ and CD8+ T lymphocytes in CIN I, CIN II and CIN III patients with and without HPV infection. Sixty-two patients were enrolled in the study. Each patient underwent a colposcopy-guided cervical biopsy. FOXP3+ lymphocytes and CD4+,CD8+ lymphocytes were detected by immunostaining in tissue samples obtained from a control group (n = 10), patients with CIN I (n = 20), CIN II (n = 14) and CIN III (n = 18) lesions. HPV was assayed by Aptima. The results showed that the numbers of CD4+ T lymphocytes did not differ between patients with CIN I, CIN II, and CIN III. However, patients with CIN II and CIN III had significantly upregulated CD8+T lymphocytes compared to patients with CIN I. In addition, patients with CIN II and CIN III had increased FOXP3 + T lymphocytes compared with patients with CIN I, which was associated with HPV status. Upregulation of FOXP3+ regulatory T lymphocytes and CD8-positive lymphocytes in patients with CIN II and CIN III suggested a pivotal role of T regulatory lymphocytes and CD8+ lymphocytes for counteracting the host immune response in the progression from CIN I to CIN II and CIN III.
KW - cervical intraepithelial neoplasia (CIN)
KW - HPV (human papilloma virus)
KW - lymphocytes
UR - http://www.scopus.com/inward/record.url?scp=85142324995&partnerID=8YFLogxK
UR - https://www-webofscience-com.db.rsu.lv/wos/alldb/full-record/BCI:BCI202200533912
U2 - 10.2478/prolas-2022-0033
DO - 10.2478/prolas-2022-0033
M3 - Article
AN - SCOPUS:85142324995
SN - 1407-009X
VL - 76
SP - 218
EP - 224
JO - Proceedings of the Latvian Academy of Sciences, Section B: Natural, Exact, and Applied Sciences
JF - Proceedings of the Latvian Academy of Sciences, Section B: Natural, Exact, and Applied Sciences
IS - 2
ER -